

B E1

lication (19) GB (11) 2 271 111 (13) A

(43) Date of A Publication 06.04.1994

(21) Application No 9320077.2

(22) Date of Filing 29.05.1993

(30) Priority Data

(31) 9220571

(32) 30.09.1992

(33) GB

(71) Applicant(s)

Zeneca Limited

(Incorporated in the United Kingdom)

Imperial Chemical House, 9 Millbank, LONDON,
SW1P 3JF, United Kingdom

British Technology Group Limited

(Incorporated in the United Kingdom)

101 Newington Causeway, LONDON, SE1 6BU,
United Kingdom

(72) and (74) continued overleaf

(51) INT CL⁵

C07D 239/90, A61K 31/505, C07D 401/00 403/02,
C07F 9/6512 // (C07D 401/00 211:00 213:00 239:90) (C07D 403/02 239:90 295:00) (C07D 413/02 239:90 295:00)

(52) UK CL (Edition M)

C2C CAA CLW CLY CLZ CRL CRM CRQ CSJ C1530
C1532 C1562 C1604 C1626 C202 C213 C215 C22Y C220
C226 C246 C247 C25Y C250 C251 C252 C255 C28X
C29Y C292 C30Y C31Y C311 C32Y C323 C326 C332
C351 C352 C355 C36Y C360 C361 C364 C366 C367
C368 C369 C396 C51X C512 C520 C537 C612 C613
C614 C615 C620 C621 C628 C630 C635 C650 C651
C660 C665 C666 C670 C697 C699 C80Y C801
C2P PA PA1 P13 P14 P14A P19E P2E P26B P7 P9
U1S S1313

(56) Documents Cited


EP 0365763 A EP 0316657 A

(58) Field of Search

UK CL (Edition L) C2C CLW CLZ CRM CSJ
INT CL⁵ C07D
ONLINE DATABASE: CAS ONLINE

(54) Quinazoline derivatives

(57) Quinazoline derivatives of the formula I



wherein

R¹ is hydrogen or a defined substituent, e.g. amino, (1 - 4C) alkyl and (1 - 4C) alkoxy;

R² is hydrogen, (1 - 4C) alkyl, which can be substituted by certain substituents (3 - 4C) alkenyl or (3 - 4C) alkynyl;

Ar¹ is phenylene or a 5- or 6-membered aromatic heterocyclene ring;

Ar² is optionally substituted phenyl or heteroaryl; and

Q is a defined substituent e.g. nitro, cyano, carbamoyl, (1 - 4C) alkylsulphonyl and N,N-di-[(1 - 4C) alkyl]sulphamoyl;

or pharmaceutically-acceptable salts thereof; are useful as anti-tumour agents.


GB 2271111 A

94094460

BEST AVAILABLE COPY

3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino]benzoate and the appropriate nucleophile was used in place of benzyl methyl sulphone there were obtained the quinazoline derivatives described in the following Table, the structures of which were confirmed by proton magnetic resonance and mass spectroscopy and by elemental analysis.

TABLE I




Example 6 Compound No.	R ^a	Q	x	m.p. (°C)
1 ^a	H	cyano	-	113-115
2	Me	methylsulphonyl	0.5	236-242
3 ^b	Me	isopropylsulphonyl	0.5	190-194
4 ^c	Me	isopropylsulphonyl	0.2	262-265
5 ^d	Me	benzylsulphonyl	0.7	279-281
6 ^e	H	N,N-dimethylsulphamoyl	0.4	122-124
7 ^{e,f}	Me	N,N-dimethylsulphamoyl	-	143-151
8 ^g	Me	N-methylsulphamoyl	-	134-153
9 ^h	Me	morpholinosulphonyl	0.5	166-170

Notes

a. The product was purified by reverse-phase chromatography using decreasingly polar mixtures of water, methanol and trifluoroacetic acid as eluent. The product so obtained contained

mass spectroscopy and by elemental analysis.

TABLE II



Example 17 Compound No.	R ^b	Ar ²	Q'	m.p. (°C)
1 ^a	H	3-pyridyl	methyl	190-192
2 ^b	F	p-fluorophenyl	methyl	171-173
3 ^c	F	p-cyanophenyl	methyl	173-174
4 ^d	F	p-fluorophenyl	4-pyridyl	198-199
5	H	p-fluorophenyl	methyl	163-166
6 ^e	F	p-tolyl	methyl	-
7 ^f	H	p-fluorophenyl	dimethylamino	163-165
8	H	p-fluorophenyl	morpholino	155-158
9 ^g	F	p-fluorophenyl	N-(2-dimethyl- aminoethyl)-N- methylamino	134-135
10 ^h	F	p-fluorophenyl	4- <u>tert</u> -butoxy- carbonyl- piperidin-1-yl	142-144
11 ⁱ	F	2-pyridyl	methyl	-
12 ^j	F	3-pyridyl	methyl	173-175


Notes

a.

The product contained 1 equivalent of water.
The methyl 3-pyridylmethyl sulphone used as a starting

CLAIMS

1. A quinazoline derivative of the formula I



wherein R¹ is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino, piperidino, morpholino, piperazin-1-yl, 4-[(1-4C)alkyl]piperazin-1-yl, 4-[(2-4C)alkanoyl]piperazin-1-yl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-(1-4C)alkyl, 4-[(1-4C)alkyl]piperazin-1-yl-(1-4C)alkyl, 4-[(2-4C)alkanoyl]piperazin-1-yl-(1-4C)alkyl, N-[hydroxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[hydroxy-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[hydroxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkoxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkoxy-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[(1-4C)alkoxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, N-[di-(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, N-[di-(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[di-(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, carboxy-(2-4C)alkanoyloxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, hydroxy-

the quinazoline ring may optionally bear at the 5-, 7- or 8-position one further substituent selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy;

R^2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy-(2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl;

Ar^1 is phenylene or a 5- or 6-membered aromatic heterocyclene ring which contains up to 3 heteroatoms selected from nitrogen and sulphur, each of which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy;

Ar^2 is phenyl or heteroaryl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy; and

Q is nitro, cyano, carbamoyl, sulphamoyl, (1-4C)alkoxycarbonyl, di-[(1-4C)alkoxy]phosphoryl, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl, phenylthio, phenylsulphinyl, phenylsulphonyl, phenyl-(1-4C)alkylthio, phenyl-(1-4C)alkylsulphinyl, phenyl-(1-4C)alkylsulphonyl, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, heteroaryl-(1-4C)alkylthio, heteroaryl-(1-4C)alkylsulphinyl, heteroaryl-(1-4C)alkylsulphonyl, N -(1-4C)alkylcarbamoyl, N,N -di-[(1-4C)alkyl]carbamoyl, N -(1-4C)alkylsulphamoyl, N,N -di-[(1-4C)alkyl]sulphamoyl, morpholino-sulphonyl, piperidinosulphonyl, piperazin-1-ylsulphonyl or 4-(1-4C)-alkylpiperazin-1-ylsulphonyl, and when Q is a group comprising a phenyl or heteroaryl group, said phenyl or heteroaryl group may optionally bear one substituent selected from halogeno, cyano, hydroxy, amino, (1-4C)alkyl and (1-4C)alkoxy;

and wherein the heteroaryl group when Ar^2 is heteroaryl, or the heteroaryl group when Q is a heteroaryl-containing group, is a 5- or 6-membered heteroaryl ring which contains 1 or 2 nitrogen heteroatoms and optionally contains a further heteroatom selected from nitrogen, oxygen and sulphur; or a pharmaceutically-acceptable salt thereof.

2. A quinazoline derivative of the formula I as defined in claim 1 wherein, in addition, Q is 4-(1-4C)alkoxycarbonylpiperazin-1-

ylsulphonyl, N-[amino-(2-4C)alkyl]sulphamoyl,
N-[(1-4C)alkylamino-(2-4C)alkyl]sulphamoyl, N-(di-[(1-4C)alkyl]amino-
(2-4C)alkyl)sulphamoyl, N-(1-4C)alkyl-N-[amino-(2-4C)alkyl]sulphamoyl,
N-(1-4C)alkyl-N-[(1-4C)alkylamino-(2-4C)alkyl]sulphamoyl or
N-(1-4C)alkyl-N-(di-[(1-4C)alkyl]amino-(2-4C)alkyl)sulphamoyl;
or a pharmaceutically-acceptable salt thereof.

3. A quinazoline derivative of the formula I as claimed in claim 1 wherein R^1 is methyl, hydroxymethyl, methoxymethyl, methylaminomethyl, dimethylaminomethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl or 4-methylpiperazin-1-ylmethyl; the quinazoline ring may optionally bear a 7-fluoro, 7-chloro or 7-methyl substituent;
 R^2 is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl;
 Ar^1 is 1,4-phenylene which may optionally bear one fluoro substituent, or Ar^1 is thiophene-2,5-diyl or thiazole-2,5-diyl with the group -CO-CH(Ar^2)(Q) in the 2-position;
 Ar^2 is phenyl which may optionally bear a substituent selected from fluoro, chloro, nitro, trifluoromethyl or methyl; and
Q is nitro, cyano, carbamoyl, sulphamoyl, methoxycarbonyl, ethoxycarbonyl, dimethoxyphosphoryl, diethoxyphosphoryl, methylsulphinyl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphinyl, phenylsulphonyl, benzylsulphinyl, benzylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl or morpholinosulphonyl;
or a pharmaceutically-acceptable salt thereof.

4. A quinazoline derivative of the formula I as claimed in claim 1 or claim 2
wherein R^1 is methyl;
the quinazoline ring may optionally bear a 7-methyl substituent;
 R^2 is methyl or prop-2-ynyl;
 Ar^1 is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group -CO-CH(Ar^2)(Q) in the 1-position) or pyridine-2,5-diyl (with the group -CO-CH(Ar^2)(Q) in the 2-position);
 Ar^2 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-nitrophenyl,

4-cyanophenyl, 2-pyridyl or 3-pyridyl; and
Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl,
isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl,
4-pyridylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl,
morpholinosulphonyl, piperazin-1-ylsulphonyl or
N-methyl-N-(2-dimethylaminoethyl)sulphamoyl;
or a pharmaceutically-acceptable salt thereof.

5. A quinazoline derivative of the formula I as claimed in claim
1 or claim 2

wherein R^1 is methyl;

the quinazoline ring may optionally bear a 7-methyl substituent;

R^2 is methyl or prop-2-ynyl;

Ar^1 is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group
-CO-CH(Ar^2)(Q) in the 1-position) or pyridine-2,5-diyl (with the group
-CO-CH(Ar^2)(Q) in the 2-position);

Ar^2 is phenyl, 3-fluorophenyl, 4-fluorophenyl or 3-pyridyl; and

Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl,
isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl,
4-pyridylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl or
morpholinosulphonyl;

or a pharmaceutically-acceptable salt thereof.

6. A quinazoline derivative of the formula I, or a
pharmaceutically-acceptable salt thereof, as claimed in claim 1,
selected from:-

4-[N-(2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -methylsulphonyldesoxybenzoin,

4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -methylsulphonyldesoxybenzoin and


N,N-dimethyl- α -[p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]- α -toluenesulphonamide.

7. A quinazoline derivative of the formula I, or a
pharmaceutically-acceptable salt thereof, as claimed in claim 1 or
claim 2, selected from:-

4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -isopropylsulphonyldesoxybenzoin,
 N,N-dimethyl-p-fluoro- α -{p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl}- α -toluenesulphonamide, 2,4'-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -methylsulphonyldesoxybenzoin, N,N-dimethyl-p-fluoro- α -{o-fluoro-p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl}- α -toluenesulphonamide,
 4'-fluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -methylsulphonyldesoxybenzoin,
 2,4'-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]- α -morpholinosulphonyldesoxybenzoin,
 α -[5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]pyridine-2-carbonyl]-p-fluoro-N,N-dimethyl- α -toluenesulphonamide and
 4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]phenyl 1-methylsulphonyl-1-(3-pyridyl)methyl ketone.


8. A process for the preparation of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 which comprises:-

(a) the reaction of an acid of the formula II




or a reactive derivative thereof, wherein R³ is hydrogen or a protecting group, with a compound of the formula Ar²-CH₂-Q;

(b) the reaction of a compound of the formula III



III

wherein R^3 has the meaning defined above and Z is a displaceable group, with an amine of the formula:



(c) for the production of a compound of the formula I wherein Q is a group which comprises a sulphonyl or sulphonyl group, the oxidation of the corresponding compound of the formula I wherein Q is a group which comprises a thio group;

(d) for the production of a compound of the formula I wherein R^1 is amino-(1-4C)alkyl or substituted-amino-(1-4C)alkyl, the reaction of a compound of the formula I wherein R^1 is hydroxy-(1-4C)alkyl, or a reactive derivative thereof, with ammonia or a substituted-amine;

(e) for the production of a compound of the formula I wherein R^1 is (2-4C)alkanoyloxy-(1-4C)alkyl or substituted-(2-4C)alkanoyloxy-(1-4C)alkyl, the reaction of a compound of the formula I wherein R^1 is hydroxy-(1-4C)alkyl with an acylating reagent; and

(f) for the production of a compound of the formula I wherein Q is a piperazin-1-ylsulphonyl group, the cleavage of a compound of the formula I wherein Q is a 4-(1-4C)alkoxycarbonylpiperazin-1-yl group; and when a pharmaceutically-acceptable salt of a compound of the formula I is required, it may be obtained by reaction of said compound with a suitable acid or base using a conventional procedure; and when an optically active form of a compound of the formula I is required, it may be obtained by carrying out one of the aforesaid processes using an optically active starting material, or by resolution of a racemic form of said compound using a conventional procedure.

9. A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 in association with a pharmaceutically-acceptable diluent or carrier.

10. The use of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 in the manufacture of a novel medicament for use in the production of an anti-tumour effect in a warm-blooded animal.

TS37204

01SEP93

BST/MB

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.